Latest Conference Articles

March 22nd 2019, 10:24pm

NCCN Annual Conference

In recent years, pancreatic has passed breast cancer as the third leading cause of cancer death in the United States, and by 2030 it could be the leading cause.

March 22nd 2019, 8:56pm

NCCN Annual Conference

The 2019 National Comprehensive Cancer Network guideline on the management of advanced clear cell renal cell carcinoma undergoes a major shift in risk category used to define preferred and alternative first-line treatments.

March 22nd 2019, 7:54pm

NCCN Annual Conference

​​John H. Ward, MD, discusses his preferences in multilane testing for patients with hormone receptor–positive, node-negative breast cancer.

March 22nd 2019, 7:34pm

NCCN Annual Conference

Gary H. Lyman, MD, MPH, medical oncologist, Fred Hutchinson Cancer Research Center, discusses the differences in approving a biosimilar and the original biologic product during the 2019 NCCN Annual Conference.

March 21st 2019, 11:34pm

NCCN Annual Conference

Matthew A. Gubens, MD, MS, discusses an update to the NCCN Guidelines regarding patients with PD-L1 non–small cell lung cancer.

March 20th 2019, 1:14am

SGO Annual Meeting

Patients with recurrent or advanced endometrial cancer demonstrated an overall response rate of almost 30% with dostarlimab treatment.

March 19th 2019, 11:32pm

SGO Annual Meeting

Combination use of olaparib and neratinib may represent a novel therapeutic option for chemotherapy-resistant patients with HER2-positive, homologous recombination–proficient ovarian cancer tumors.

March 19th 2019, 9:55pm

SGO Annual Meeting

The addition of the dendritic cell-based immunotherapy DCVAC/OvCA to standard carboplatin and gemcitabine led to a significant improvement in overall survival in patients with relapsed, platinum-sensitive, epithelial ovarian cancer.

March 19th 2019, 9:03pm

SGO Annual Meeting

David S. Hong, MD, deputy director of the Department of investigational Cancer Therapeutics and associate vice president of clinical research at The University of Texas MD Anderson Cancer Center, discusses the promising results of the phase II innovaTV 201 study, in which tisotumab vedotin was used to treat patients with previously treated recurrent or metastatic cervical cancer.

March 19th 2019, 7:49pm

SGO Annual Meeting

Karen H. Lu, MD, professor and chair in the Department of Gynecologic Oncology and Reproductive Medicine at The University of Texas MD Anderson Cancer Center discusses the challenges of risk-reducing salpingo-oophorectomy in women with an increased risk for hereditary ovarian cancer.

March 19th 2019, 2:19am

SGO Annual Meeting

Treatment with neratinib led to a clinical benefit rate of 54.5% in patients with HER2-mutant cervical cancer.

March 18th 2019, 8:45pm

SGO Annual Meeting

Jonathan Ledermann, MD, professor of medical oncology at UCL Cancer Institute in London, discusses the growing use of PARP inhibitors in maintenance therapy for ovarian cancer in an interview during the 2019 SGO Annual Meeting.

March 18th 2019, 7:48pm

SGO Annual Meeting

Combination therapy with pembrolizumab, bevacizumab, and metronomic cyclophosphamide induced a 95% disease control rate and 40% overall response rate among women with recurrent ovarian cancer.

March 18th 2019, 7:02pm

SGO Annual Meeting

Lenvatinib in combination with weekly paclitaxel induced activity among those with recurrent endometrial and platinum-resistant epithelial ovarian cancer, resulting in a 65% overall response rate.

March 18th 2019, 6:42pm

SGO Annual Meeting

Emese Zsiros, MD, PhD, discusses the results of her recent phase II trial that set out to evaluate the use of pembrolizumab in combination with bevacizumab and oral metronomic cyclophosphamide in the treatment of patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer.

March 18th 2019, 12:07am

SGO Annual Meeting

Kathleen N. Moore, MD, associate director for clinical research, gynecologic oncologist at The Stephenson Cancer Center, The University of Oklahoma, explores the impact of the SOLO-1 trial in the field of ovarian cancer, in particular, the benefits olaparib provides and the light it shines on the importance of using genetic testing to inform treatment decisions.

March 17th 2019, 7:45pm

SGO Annual Meeting

Adverse events decreased among patients with high-risk ovarian cancer who received a 200- or 300-mg individualized starting dose of niraparib, based upon baseline bodyweight and platelet count, compared with a 300-mg fixed starting dose.

March 17th 2019, 6:10pm

SGO Annual Meeting

Prior exposure to PARP inhibitor treatment may not lead to resistance in future use with these agents in women with recurrent epithelial ovarian cancer, suggesting that repeat use could become more common.

March 17th 2019, 5:24pm

SGO Annual Meeting

Robert Coleman, MD, professor in the Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, discusses the effect of age on the efficacy of rucaparib (Rubraca) in patients with recurrent ovarian carcinoma.

March 17th 2019, 1:52am

SGO Annual Meeting

Patients with recurrent ovarian cancer who received niraparib maintenance therapy experienced more progression-free time without experiencing symptoms or toxicity compared with placebo; the benefit was 4-fold for those with germline (g) BRCA-mutated disease and 2-fold for non-gBRCA-mutated ovarian cancer.